Compare Adaptive Biotechnologies Corp (ADPT) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Extra Space Storage, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Extra Space Storage, Inc. trades at $144.93 (market cap $31.21B). The key difference: Extra Space Storage, Inc. is far larger — about 9.4× Adaptive Biotechnologies Corp's market cap, and Extra Space Storage, Inc. pays a 4.39% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EXR | |
|---|---|---|
Market Cap | $3.33B | $31.21B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $152.75 |
52-Week Low | $10.24 | $126.67 |
Enterprise Value | $3.19B | $45.01B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EXR trades at $147.73, down 1.04% on the day, with a neutral technical signal and strong fundamentals including a 27.66% net income margin and consistent earnings beats. The company maintains robust cash flow from operations at $1.85B in 2025 and recently priced $550 million in senior notes. Analyst consensus is mixed with a $152.86 price target, while technical support sits at $144.
Outlook remains stable with revenue growth and dividend reliability, but risks include high leverage with a 46.63% debt-to-asset ratio and competitive pressures. The stock offers value near consensus targets, though margin compression and interest rate sensitivity warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
